Erlotinib Hydrochloride (CP 358,774)

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Also Known As:

CP 358,774; Tarceva; 11C-erlotinib; CP 358774; CP-358,774; CP-358774; Erlotinib; Erlotinib HCl; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; OSI-774; 11C erlotinib; 358,774, CP; 358774, CP; CP358,774; CP358774; HCl, Erlotinib; Hydrochloride, Erlotinib; OSI 774; OSI774

Networked: 4349 relevant articles (645 outcomes, 1250 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - Erlotinib Hydrochloride: 4349

Experts

1.	Jänne, Pasi A: 58 articles (11/2021 - 05/2005)
2.	Pao, William: 45 articles (01/2018 - 09/2004)
3.	Nakagawa, Kazuhiko: 43 articles (01/2022 - 03/2007)
4.	Miller, Vincent A: 40 articles (11/2017 - 01/2005)
5.	Kris, Mark G: 36 articles (01/2021 - 01/2005)
6.	Johnson, Bruce E: 35 articles (11/2021 - 05/2005)
7.	Rosell, Rafael: 35 articles (10/2019 - 03/2006)
8.	Riely, Gregory J: 31 articles (01/2021 - 01/2005)
9.	Mitsudomi, Tetsuya: 29 articles (12/2021 - 06/2006)
10.	Shepherd, Frances A: 28 articles (01/2019 - 07/2005)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/01/2006 - "Developmental studies of either drug have failed to show synergistic effects when combined with cytotoxic drugs as the first line treatment in patients with advanced non-small cell lung cancer, but erlotinib has shown survival prolongation when compared with best supportive care in patients with recurrence. " 06/01/2012 - "However, two recent clinical case reports showed that erlotinib caused complete remission of acute myeloid leukaemia (AML)-M1 in patients who had both AML-M1 and non-small-cell lung cancer. " 03/01/2021 - "This study aimed to demonstrate that having clinical pharmacist as a member of oncology team in low and middle income countries might lead to significant reduction in the number of erlotinib interactions in the treatment of non-small cell lung cancer patients. " 09/01/2006 - "The objective of this study was to determine the tolerability and efficacy of high-dose erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer (NSCLC). " 09/01/2013 - "A randomized trial carried out by Shepherd et al. in patients with advanced or metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over placebo in prolonging overall survival and progression-free survival. "
2.	Neoplasms (Cancer) 01/01/2017 - "In in vivo tumorigenicity assay, oral induction of erlotinib also dramatically reduced the growth of Y79 tumor grafts. " 11/17/2015 - "We found that intermittent high-dose treatment with erlotinib induced apoptosis more potently and improved tumor shrinkage significantly than the established low doses. " 11/15/2015 - "When combined with the EGFR-targeted drug erlotinib, DLL-1 significantly improved progression-free survival by inducing robust tumor-specific T-cell immunity. " 10/01/2013 - "The mouse tumor model demonstrated a significant reduction in NPC tumor volume in mice treated with erlotinib in combination with radiation when compared with that in mice treated with radiation alone. " 04/01/2023 - "The obtained compounds (2-8) were found to be more effective against the two tested cancer cell lines than erlotinib. "
3.	Lung Neoplasms (Lung Cancer) 01/01/2020 - "Oral gavage of these responder bacteria significantly increased the efficacy of erlotinib and induced the expression of CXCL9 and IFN-γ in a murine lung cancer model. " 11/17/2015 - "Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer." 02/01/2019 - "Present study has shown a premise to improve therapeutic efficacy against erlotinib-resistant lung cancer using modified nanoErlo formulations." 08/20/2006 - "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21." 10/01/2021 - "We investigated the efficacy of low-dose first-line erlotinib and its effects on the quality of life of older patients with lung cancer. "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 08/09/2011 - "The CAF-AsPC-1 pancreatic cancer xenografts reached significantly greater tumour volume than those xenografts lacking CAF and were resistant to the anti-tumour effects of EGFR inhibition with erlotinib. " 01/01/2018 - "Downregulation of GEP100 Improved the Growth Inhibition Effect of Erlotinib Through Modulating Mesenchymal Epithelial Transition Process in Pancreatic Cancer." 11/01/2013 - "We evaluated the efficacy of erlotinib plus GEM in patients with unresectable pancreatic cancer. " 04/01/2021 - "A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial." 03/26/2021 - "The aim of this study was to evaluate whether knockdown of DJ-1 expression can sensitize pancreatic cancer cells to erlotinib treatment. "
5.	Neoplasm Metastasis (Metastasis) 10/01/2011 - "As seen in this patient, high CSF concentrations of erlotinib can be achieved by high-dose administration, and this finding suggests the efficacy of high-dose administration, especially to refractory CNS metastases of NSCLC patients." 10/01/2013 - "Finally, erlotinib is expected to be effective in the treatment of brain metastasis." 12/01/2018 - "Here, we investigated the efficacy of water-soluble erlotinib (NUFS-sErt) against these metastases. " 05/01/2016 - "Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion." 01/26/2016 - "The cohort was stratified based on the presence or absence of hepatic metastases and the efficacy of erlotinib was defined based on disease control rate (DCR) and progression-free survival (PFS). "

Related Drugs and Biologics

1.	ErbB Receptors (EGF Receptor)
2.	Gefitinib (Iressa)
3.	Tyrosine Kinase Inhibitors
4.	Bevacizumab (Avastin)
5.	Gemcitabine
6.	Afatinib
7.	Erlotinib Hydrochloride (CP 358,774)
8.	osimertinib
9.	Cetuximab (Erbitux)
10.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Chemoradiotherapy
5.	Neoadjuvant Therapy